...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Comments re AHA presentation

 

In fact, a higher rate of non-compliance in the high LDL group might explain why this group did more poorly with both the placebo and the drug than the low LDL group.  The poor placebo performance reflects poor statin compliance alone whereas the poor apabetalone performance reflects poor statin compliance perhaps compounded by poor apabetalone compliance as well.  Just a possibility, but plausible.

Jupe

Share
New Message
Please login to post a reply